| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 55 | CN 6 | 98.08 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 280 | CN 2 | 99.26 |
| Cardiac Arrhythmias and Treatments | Lifetime | 560 | CN 6 | 98.54 |
| Cardiac electrophysiology and arrhythmias | Lifetime | 624 | CN 4 | 98.51 |
| ECG Monitoring and Analysis | Lifetime | 207 | CN 7 | 97.55 |
| Gout, Hyperuricemia, Uric Acid | Lifetime | 537 | CN 50 | 91.43 |
| Boron Compounds in Chemistry | Lifetime | 707 | CN 62 | 89.65 |
| Takotsubo Cardiomyopathy and Associated Phenomena | Lifetime | 791 | CN 8 | 76.54 |
| Infectious Disease Case Reports and Treatments | Lifetime | 731 | CN 10 | 66.70 |
| Reliability and Agreement in Measurement | Lifetime | 659 | CN 18 | 60.98 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 25 | CN 14 | 96.77 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 221 | CN 6 | 98.32 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 239 | CN 7 | 98.21 |
| Cardiac electrophysiology and arrhythmias | 2021-2025 | 134 | CN 2 | 97.71 |
| Nutrition and Health in Aging | 2021-2025 | 505 | CN 63 | 94.67 |
| Peptidase Inhibition and Analysis | 2021-2025 | 388 | CN 98 | 92.80 |
| ECG Monitoring and Analysis | 2021-2025 | 190 | CN 44 | 92.07 |
| Diabetes Treatment and Management | 2021-2025 | 570 | CN 30 | 94.16 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 418 | CN 87 | 91.34 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 165 | CN 9 | 90.13 |
| Gout, Hyperuricemia, Uric Acid | 2021-2025 | 156 | CN 57 | 88.24 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 712 | CN 282 | 86.42 |
| Endoplasmic Reticulum Stress and Disease | 2021-2025 | 314 | CN 76 | 84.78 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 405 | CN 75 | 85.48 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 568 | CN 71 | 85.90 |
| Cardiac Health and Mental Health | 2021-2025 | 636 | CN 44 | 85.73 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 801 | CN 135 | 83.29 |
| HER2/EGFR in Cancer Research | 2021-2025 | 974 | CN 151 | 84.81 |
| Ion channel regulation and function | 2021-2025 | 619 | CN 67 | 81.22 |
| Pericarditis and Cardiac Tamponade | 2021-2025 | 159 | CN 7 | 78.66 |
| Potassium and Related Disorders | 2021-2025 | 259 | CN 7 | 79.12 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 785 | CN 182 | 78.35 |
| Boron Compounds in Chemistry | 2021-2025 | 245 | CN 62 | 77.92 |
| Cardiovascular Syncope and Autonomic Disorders | 2021-2025 | 476 | CN 23 | 76.52 |
| Cardiac Fibrosis and Remodeling | 2021-2025 | 510 | CN 197 | 72.28 |
| Takotsubo Cardiomyopathy and Associated Phenomena | 2021-2025 | 347 | CN 19 | 61.35 |